Comparative Study of the Change in Liver Enzymes After General or Spinal Anesthetic Techniques in Patients With Preoperatively Elevated Liver Enzymes.
Comparative Study of the Change in Liver Enzymes After General or Spinal Anesthetic Techniques in Patients With Preoperatively Elevated Liver Enzymes
- To assess the changes in liver functions postoperatively in patients with preoperatively elevated liver enzymes.
- To identify the most appropriate anesthesia technique for patients with preoperatively elevated liver enzymes.
- To assess the effect of intraoperative event (bleeding, hypoxia, hypotension, prolonged operation) on liver functions in these patients.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Surgery and anesthesia are stressful events, thus there is a possibility that liver enzymes and bilirubin may increase postoperatively. Mild elevations of serum aminotransferase, alkaline phosphatase, or bilirubin levels are frequent after surgical procedures, whether performed under general or spinal anesthesia. Anesthesia causes an initial reduction in hepatic arterial blood flow of 35-42% in the first 30 min of induction of anesthesia. During surgery, The liver blood flow returns to baseline. It is possible that either the initial hypoperfusion or reperfusion injury, or both, may contribute to postoperative liver dysfunction when it occurs.
The type of surgery is potentially an important factor of postoperative hepatic dysfunction. Intra-abdominal operations are more likely than extra-abdominal surgeries to cause reflex systemic hypotension and to subsequently reduce hepatic blood flow.This could be due to traction on abdominal viscera. Hypercarbia-induced splanchnic vasoconstriction is also a threat to hepatic perfusion in laparoscopic surgery. Surgeries that result in a large amount of blood loss increase the risk for ischemic hepatic injury, as can intraoperative hypotension.
Liver disease is important to recognize preoperatively because the risk of surgery in patients with advanced disease can be grave.Patients with liver disease are more likely than patients without liver disease to experience hepatic decompensation with anesthesia. Measurement of serum Bilirubin levels is central to the evaluation of hepatobiliary disorders. Liver disease is a challenging condition for the anesthesiologist, However, the risk could be diminished by careful consideration of the patients' condition preoperatively and choosing suitable anesthetic procedure and drugs for these patients.Meanwhile, The effect of performing spinal anesthesia on patients with liver disease has not been investigated properly as most studies excluded patients with preoperatively elevated liver enzymes. Studies on patients undergoing general anesthesia with normal preoperative liver function tests showed a transient increase in the level of AST& ALT, with a mild increase in postoperative bilirubin levels
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Cairo, Egypt, 11451
- Ahmed Abdalla Mohamed
-
Cairo, Egypt, 11451
- Ahmed Abdalla
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
60 Patients are randomly divided by computer designed lists and then concealed in closed envelopes into 2 equal groups:
- Group A(n=30),in which general anesthesia technique is used
- Group B(n=30),in which regional anesthesia technique is used
Description
Inclusion Criteria:
Adult healthy ASA I, II patients, both genders, aged 18 - 60 years, with stationary elevated liver enzymes < 2 folds undergoing elective lower abdominal wall or limb surgeries with expected operation time less than 2 hours
Exclusion Criteria:
- ASA class III or IV
- Age >60 years or <18 years
- Patients undergoing intraperitoneal and laparoscopic procedures.
- Acute viral hepatitis: inflammation of the liver caused by infection with one of the five hepatitis viruses. In most people, the inflammation begins suddenly and lasts only a few weeks.
- Acute alcoholic hepatitis: is inflammation of the liver due to excessive intake of alcohol. It is usually found in association with fatty liver, an early stage of alcoholic liver disease, and may contribute to the progression of fibrosis, leading to cirrhosis.
- Severe chronic hepatitis: is inflammation of the liver that lasts at least 6 months.
- Child's C class classification: this score is used to assess the prognosis of chronic liver disease, mainly cirrhosis.
- Severe coagulopathy: a pathological condition that reduces the ability of the blood to coagulate, resulting in uncontrolled bleeding. A platelet count of < 50 x 109 /L will be considered at high risk of increased bleeding.
- Severe extrahepatic complication (Hypoxemia, Acute renal failure…)
- Pregnant, diabetic patients
- Patients having an auto-immune disease
- Patients taking anticoagulant drugs or drugs that cause elevated liver enzymes (non-steroidal anti-inflammatory drugs, antibiotics, antiepileptic drugs, inhibitors of hydroxyl-methyl-glutaryl-coenzyme a reductase (statins), and anti-tuberculosis drugs) were excluded from the study
Study Plan
How is the study designed?
Design Details
- Observational Models: Cohort
- Time Perspectives: Prospective
Cohorts and Interventions
Group / Cohort |
Intervention / Treatment |
|---|---|
|
Group A
General anesthesia technique
|
general anesthesia and regional anesthesia techniques are used
Other Names:
|
|
Group B
Regional anesthesia technique
|
general anesthesia and regional anesthesia techniques are used
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Compare the pre and postoperative liver enzymes
Time Frame: 24 hours from the start
|
The pre and 24 hours postoperative AST levels of patients in the general anaesthesia group and spinal anaesthesia group
|
24 hours from the start
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Changes in Liver function tests (AST, ALT, total and direct Bilirubin) from the preoperative values to 48 hours postoperative
Time Frame: During Operation and 48 hours postoperative
|
To determine the changes in Liver function tests (AST, ALT, total and direct Bilirubin) from the preoperative values to 48 hours postoperative
|
During Operation and 48 hours postoperative
|
|
Intraoperative monitoring and correlation with the change of the liver enzymes postoperative
Time Frame: During Operation and 48 hours postoperative
|
To monitor the intraoperative vital signs (Blood pressure and Heart rate), the intraoperative blood loss and total fluid consumptions, the total consumptions of the vasopressors, the intraoperative adverse events(severe hypotension, bleeding, blood transfusion, hypoxia, hepatotoxic drugs …) and correlate it to the change of the liver enzymes postoperative
|
During Operation and 48 hours postoperative
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Norhan abd Aleem Ali, M.D, Cairo University
- Principal Investigator: Shady Abo El ela Ismaiel, Ph.D, Cairo University
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- N 30-2017/Ms
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
- To identify the most appropriate anesthesia technique for HCV +ve patients.
- To assess the changes in liver functions & APRI score preoperative and postoperative in HCV +ve patients.
- To assess the effect of intraoperative event (bleeding,hypoxia (bleeding,hypoxia,hypotension,prolonged operation )and postoperative events on liver functions in HCV +ve patients
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.